ATH 25.0% 0.5¢ alterity therapeutics limited

Another short trial was snuck in...

  1. 1,847 Posts.
    lightbulb Created with Sketch. 1
    Absorption, Metabolism and Excretion Study of [14C]PBT2 and Absolute Bioavailability of PBT2

    This study has been completed.
    Sponsor:
    Prana Biotechnology Limited
    Information provided by (Responsible Party):
    Prana Biotechnology Limited
    ClinicalTrials.gov Identifier:
    NCT02249728
    First received: July 30, 2014
    Last updated: September 25, 2014
    Last verified: September 2014

    The purpose of the study is to investigate how the test drug, PBT2, is taken up, broken down and removed from the body when given as an oral capsule, a radiolabelled oral suspension and a radiolabelled intravenous injection.

    Condition Intervention Phase
    1 Healthy Volunteers Drug: IV PBT2 microtracer and oral PBT2 single doseDrug: oral 14C-PBT2 Phase 1

    Study Type: Interventional
    1 Study Design: Allocation: Non-RandomizedEndpoint Classification: Pharmacokinetics StudyIntervention Model: Single Group AssignmentMasking: Open LabelPrimary Purpose: Basic Science
    2 Official Title: A Phase I , Open-Label Study to Evaluate the Absorption, Metabolism and Excretion of [14C]-PBT2 and to Estimate the Absolute Bioavailability of PBT2 in Healthy Male Subjects
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.001(25.0%)
Mkt cap ! $26.19M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $27.94K 6.050M

Buyers (Bids)

No. Vol. Price($)
46 57663299 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 56205001 43
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
0.5¢
  Change
0.001 ( 0.00 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 20524121
Last updated 15.46pm 29/03/2024 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.